Posts by: Jose Marques Lopes, PhD

News

Add-on treatment with asthma medication Fasenra (benralizumab) failed to reduce annual exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), according to final results of two Phase ... Read more

March 12, 2019March 12, 2019

Dry Powder Inhaler Formulation of Ensifentrine Improves Lung Function, Phase 2 Data Show

News

Treatment with a dry powder inhaler (DPI) formulation of ensifentrine led to clinically meaningful and sustained improvement in lung function in people with moderate to severe chronic obstructive pulmonary ... Read more

August 21, 2018August 21, 2018

Autoimmune Responses May Be Behind Development of COPD, Study Suggests

News

A specific gene variation associated with chronic obstructive pulmonary disease (COPD) is also linked with autoimmune disorders, according to a large genetic study, suggesting a role for autoimmune responses in ... Read more

July 24, 2018July 24, 2018

COPD Treatment with Targeted Lung Denervation Found Safe and Feasible, Study Reports

News

Treatment of chronic obstructive pulmonary disease (COPD) with a minimally invasive investigative procedure called targeted lung denervation (TLD) is feasible, safe, and was found to improve lung function, according ... Read more

June 1, 2018June 1, 2018

#ATS2018 — New Tool Can Determine Risk of Hospitalization for COPD Patients, Study Finds

News

A newly developed tool can predict patients with chronic obstructive pulmonary disease (COPD) who are at a high risk of hospitalization due to a disease flare-up, according to a study. ... Read more

May 18, 2018May 18, 2018

AstraZeneca’s Fasenra Fails to Reduce COPD Exacerbations, Phase 3 Trial Shows

News

Top-line results of a Phase 3 trial showed that treatment candidate Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), AstraZeneca ... Read more

May 15, 2018May 15, 2018

#ATS2018 – Potential COPD Treatment, RPL554, Seen to Aid Bronchodilation in Combo with Spiriva

News

Verona Pharma’s treatment candidate for chronic obstructive pulmonary disease (COPD) RPL554 works to open the airways of the lungs, aiding bronchodilation, when used with Spiriva (tiotropium), and its newer inhaled formulation is ... Read more

May 8, 2018May 8, 2018

Blocking Cholesterol Derivative May Offer Way to Treat COPD, Study Suggests

News

Blocking a cellular pathway related to cholesterol metabolism shows early promise in treating chronic obstructive pulmonary disease (COPD), a German study in mice reports. The research, “Cholesterol metabolism promotes ... Read more

April 24, 2018April 24, 2018

Trelegy Ellipta Reduces COPD Exacerbations, Improves Lung Function and Quality of Life, Trial Shows

News

Treatment with the triple-combination therapy Trelegy Ellipta reduced exacerbations in chronic obstructive pulmonary disease (COPD) and improved patients’ lung function and quality of life, according to a Phase 3 trial. The ... Read more

April 10, 2018April 12, 2018

Treatment with Spiolto Respimat Reduces Rate of COPD Flare-ups Compared to Spiriva Respimat, Study Shows

News

Treatment of chronic obstructive pulmonary disease (COPD) patients with Spiolto Respimat (tiotropium/olodaterol) reduced the rate of moderate-to-severe exacerbations, compared to Spiriva Respimat (tiotropium bromide), in a Phase 3 clinical trial, according to Boehringer ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Add-on Fasenra Does Not Ease COPD Exacerbations, Phase 3 Results Show

Dry Powder Inhaler Formulation of Ensifentrine Improves Lung Function, Phase 2 Data Show

Autoimmune Responses May Be Behind Development of COPD, Study Suggests

COPD Treatment with Targeted Lung Denervation Found Safe and Feasible, Study Reports

#ATS2018 — New Tool Can Determine Risk of Hospitalization for COPD Patients, Study Finds

AstraZeneca’s Fasenra Fails to Reduce COPD Exacerbations, Phase 3 Trial Shows

#ATS2018 – Potential COPD Treatment, RPL554, Seen to Aid Bronchodilation in Combo with Spiriva

Blocking Cholesterol Derivative May Offer Way to Treat COPD, Study Suggests

Trelegy Ellipta Reduces COPD Exacerbations, Improves Lung Function and Quality of Life, Trial Shows

Treatment with Spiolto Respimat Reduces Rate of COPD Flare-ups Compared to Spiriva Respimat, Study Shows

Pin It on Pinterest